NEW YORK, NY / ACCESSWIRE / October 27, 2021 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
EAR Shareholders Click Here: https://www.zlk.com/pslra-1/eargo-inc-loss-submission-form?prid=20711&wire=1
NNOX Shareholders Click Here: https://www.zlk.com/pslra-1/nano-x-imaging-ltd-loss-submission-form?prid=20711&wire=1
BMRN Shareholders Click Here: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?prid=20711&wire=1
* ADDITIONAL INFORMATION BELOW *
Eargo, Inc. (NASDAQ:EAR)
EAR Lawsuit on behalf of: investors who purchased October 16, 2020 - September 22, 2021
Lead Plaintiff Deadline : December 6, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/eargo-inc-loss-submission-form?prid=20711&wire=1
According to the filed complaint, during the class period, Eargo, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) Eargo had improperly sought reimbursements from certain third-party payors; (2) the foregoing was reasonably likely to lead to regulatory scrutiny; (3) as a result and because the reimbursements at issue involved the Company's largest third-party payor, Eargo's financial results would be adversely impacted; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Nano-X Imaging Ltd. (NASDAQ:NNOX)
NNOX Lawsuit on behalf of: investors who purchased June 17, 2021 - August 18, 2021
Lead Plaintiff Deadline: December 6, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/nano-x-imaging-ltd-loss-submission-form?prid=20711&wire=1
According to the filed complaint, during the class period, Nano-X Imaging Ltd. made materially false and/or misleading statements and/or failed to disclose that: (i) Nano-X's 510(k) application for the Nanox.ARC was deficient; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the 510(k) application for the Nanox.ARC in its current form; (iii) as a result, NanoX had overstated the Nanox.ARC's regulatory and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)
BMRN Lawsuit on behalf of: investors who purchased January 13, 2020 - September 3, 2021
Lead Plaintiff Deadline : December 22, 2021
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/biomarin-pharmaceutical-inc-loss-submission-form-2?prid=20711&wire=1
According to the filed complaint, during the class period, BioMarin Pharmaceutical Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) BMN 307 was less safe than BioMarin had led investors to believe; (ii) BMN 307's safety profile made it likely that the FDA would place a clinical hold on the Phearless Phase 1/2 study; (iii) accordingly, the Company had overstated BMN 307's clinical and commercial prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP